CTRI/2008/091/000081尚未招募2 期
A Randomized, Double Blind Study of Biomarkers Predictive of Improvement in Progression Free Survival in Patients With Advanced Pancreatic Cancer Treated With Tarceva.
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •adult patients, >=18 years of age;
- •- histologically or cytologically documented locally advanced-unresectable or metastatic pancreatic cancer;
- •- measurable disease according to RECIST;
- •- failure of at least one prior chemotherapy regimen, or who are deemed unsuitable for chemotherapy;
- •- ECOG performance status of 0-2.
排除标准
- •- local or locally advanced-resectable pancreatic cancer;
- •- any other malignancies within last 5 years, except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer;
- •- major surgery within 2 weeks prior to randomization
研究者
相似试验
已完成
不适用
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancerJPRN-UMIN000010429EPS Corporation100
已完成
不适用
Research on biomarkers in "A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors"Colorectal cancerJPRN-UMIN000018412Japan Clinical Cancer Research Organization227
尚未招募
不适用
A prospective observational study of biomarkers for Second-line FOLFIRI plus Aflibercept treatment in patients with metastatic colorectal cancer comparing to FOLFIRI plus beVacizumab: an Exploratory biomarker study.colorectal cancerJPRN-UMIN000038508Kyoto University Hospital70
招募中
不适用
Pilot study: clinical evaluation of biomarkers as predictors of survival in castrate-resistant prostate cancer patients.NL-OMON34838niversitair Medisch Centrum Sint Radboud50
招募中
不适用
An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab.solid cancerJPRN-UMIN000028474Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.30